# Fate Therapeutics Inc: financial statements, quarterly

FATE · Nasdaq · CIK 1434316 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fate.md) · [Financials](/companies/fate/financials.md) · [Filings](/companies/fate/filings.md) · [Insiders](/companies/fate/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fate/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.9](/filings/0000950170-24-125317.md) | [1.7 d](/filings/0000950170-25-033510.md) | [1.9](/filings/0000950170-25-070285.md) | [6.8](/filings/0000950170-25-107309.md) | [3.1](/filings/0001193125-25-279096.md) | [1.9 d](/filings/0001193125-26-073699.md) | [1.6](/filings/0001193125-26-220696.md) | [1.9](/filings/0001193125-26-347988.md) | [1.7](/filings/0001193125-25-279096.md) | [1.4 d](/filings/0001193125-26-073699.md) | [1.3](/filings/0001193125-26-220696.md) | [2.1](/filings/0001193125-26-347988.md) |
| Research and development | $m | [34.3](/filings/0000950170-24-125317.md) | [31.8 d](/filings/0000950170-25-033510.md) | [32.1](/filings/0000950170-25-070285.md) | [34.6](/filings/0000950170-25-107309.md) | [34.7](/filings/0001193125-25-279096.md) | [33.6 d](/filings/0001193125-26-073699.md) | [29.1](/filings/0001193125-26-220696.md) | [27.4](/filings/0001193125-26-347988.md) | [25.8](/filings/0001193125-25-279096.md) | [25.4 d](/filings/0001193125-26-073699.md) | [24.7](/filings/0001193125-26-220696.md) | [24.4](/filings/0001193125-26-347988.md) |
| Operating income | $m | [(51.3)](/filings/0000950170-24-125317.md) | [(48.1) d](/filings/0000950170-25-033510.md) | [(51.1)](/filings/0000950170-25-070285.md) | [(45.1)](/filings/0000950170-25-107309.md) | [(52.4)](/filings/0001193125-25-279096.md) | [(61.7) d](/filings/0001193125-26-073699.md) | [(41.3)](/filings/0001193125-26-220696.md) | [(37.0)](/filings/0001193125-26-347988.md) | [(34.7)](/filings/0001193125-25-279096.md) | [(34.7) d](/filings/0001193125-26-073699.md) | [(33.0)](/filings/0001193125-26-220696.md) | [(31.1)](/filings/0001193125-26-347988.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(45.2)](/filings/0000950170-24-125317.md) | [(44.1) d](/filings/0000950170-25-033510.md) | [(48.0)](/filings/0001193125-25-279096.md) | [(38.4)](/filings/0001193125-25-279096.md) | [(47.7)](/filings/0001193125-25-279096.md) | [(52.2) d](/filings/0001193125-26-073699.md) | [(37.6)](/filings/0001193125-26-347988.md) | [(34.1)](/filings/0001193125-26-347988.md) | [(32.3)](/filings/0001193125-25-279096.md) | [(32.4) d](/filings/0001193125-26-073699.md) | [(31.2)](/filings/0001193125-26-347988.md) | [(30.2)](/filings/0001193125-26-347988.md) |
| Diluted EPS | $ per share | [(0.46)](/filings/0000950170-24-125317.md) | not reported | [(0.47)](/filings/0000950170-25-070285.md) | [(0.33)](/filings/0000950170-25-107309.md) | [(0.40)](/filings/0001193125-25-279096.md) | not reported | [(0.32)](/filings/0001193125-26-220696.md) | [(0.29)](/filings/0001193125-26-347988.md) | [(0.27)](/filings/0001193125-25-279096.md) | not reported | [(0.26)](/filings/0001193125-26-220696.md) | [(0.25)](/filings/0001193125-26-347988.md) |
| Basic EPS | $ per share | [(0.46)](/filings/0000950170-24-125317.md) | not reported | [(0.47)](/filings/0000950170-25-070285.md) | [(0.33)](/filings/0000950170-25-107309.md) | [(0.40)](/filings/0001193125-25-279096.md) | not reported | [(0.32)](/filings/0001193125-26-220696.md) | [(0.29)](/filings/0001193125-26-347988.md) | [(0.27)](/filings/0001193125-25-279096.md) | not reported | [(0.26)](/filings/0001193125-26-220696.md) | [(0.25)](/filings/0001193125-26-347988.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [33.3](/filings/0000950170-24-125317.md) | [41.9](/filings/0000950170-25-033510.md) | [121](/filings/0000950170-25-070285.md) | [36.9](/filings/0000950170-25-107309.md) | [37.9](/filings/0001193125-25-279096.md) | [36.1](/filings/0001193125-26-073699.md) | [44.9](/filings/0001193125-26-220696.md) | [41.2](/filings/0001193125-26-347988.md) | [40.6](/filings/0001193125-25-279096.md) | [46.6](/filings/0001193125-26-347988.md) | [39.6](/filings/0001193125-26-220696.md) | [32.4](/filings/0001193125-26-347988.md) |
| Current assets | $m | [364](/filings/0000950170-23-061080.md) | [332](/filings/0000950170-25-033510.md) | [394](/filings/0000950170-24-056869.md) | [319](/filings/0000950170-24-096187.md) | [310](/filings/0000950170-24-125317.md) | [292](/filings/0001193125-26-073699.md) | [248](/filings/0000950170-25-070285.md) | [230](/filings/0000950170-25-107309.md) | [221](/filings/0001193125-25-279096.md) | [209](/filings/0001193125-26-347988.md) | [180](/filings/0001193125-26-220696.md) | [158](/filings/0001193125-26-347988.md) |
| Total assets | $m | [544](/filings/0000950170-23-061080.md) | [506](/filings/0000950170-25-033510.md) | [570](/filings/0000950170-24-056869.md) | [529](/filings/0000950170-24-096187.md) | [495](/filings/0000950170-24-125317.md) | [441](/filings/0001193125-26-073699.md) | [399](/filings/0000950170-25-070285.md) | [372](/filings/0000950170-25-107309.md) | [344](/filings/0001193125-25-279096.md) | [319](/filings/0001193125-26-347988.md) | [285](/filings/0001193125-26-220696.md) | [260](/filings/0001193125-26-347988.md) |
| Current liabilities | $m | [41.3](/filings/0000950170-23-061080.md) | [39.1](/filings/0000950170-25-033510.md) | [45.4](/filings/0000950170-24-056869.md) | [34.8](/filings/0000950170-24-096187.md) | [37.4](/filings/0000950170-24-125317.md) | [38.5](/filings/0001193125-26-073699.md) | [28.2](/filings/0000950170-25-070285.md) | [28.7](/filings/0000950170-25-107309.md) | [28.1](/filings/0001193125-25-279096.md) | [36.1](/filings/0001193125-26-347988.md) | [30.7](/filings/0001193125-26-220696.md) | [32.6](/filings/0001193125-26-347988.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [403](/filings/0000950170-24-125317.md) | [368](/filings/0001193125-26-073699.md) | [426](/filings/0001193125-25-279096.md) | [397](/filings/0001193125-25-279096.md) | [362](/filings/0001193125-25-279096.md) | [319](/filings/0001193125-26-347988.md) | [288](/filings/0001193125-26-347988.md) | [261](/filings/0001193125-26-347988.md) | [234](/filings/0001193125-25-279096.md) | [207](/filings/0001193125-26-347988.md) | [180](/filings/0001193125-26-347988.md) | [153](/filings/0001193125-26-347988.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(38.3) d](/filings/0000950170-24-125317.md) | [(36.6) d](/filings/0000950170-25-033510.md) | [(33.4)](/filings/0000950170-25-070285.md) | [(32.3) d](/filings/0000950170-25-107309.md) | [(29.4) d](/filings/0001193125-25-279096.md) | [(27.8) d](/filings/0001193125-26-073699.md) | [(33.8)](/filings/0001193125-26-220696.md) | [(24.6) d](/filings/0001193125-26-347988.md) | [(24.4) d](/filings/0001193125-25-279096.md) | [(23.3) d](/filings/0001193125-26-073699.md) | [(30.8)](/filings/0001193125-26-220696.md) | [(23.4)](/filings/0001193125-26-347988.md) |
| Capital expenditure | $m | [0.6 d](/filings/0000950170-24-125317.md) | [0.2 d](/filings/0000950170-25-033510.md) | [0.1](/filings/0000950170-25-070285.md) | [0.1 d](/filings/0000950170-25-107309.md) | [0.5 d](/filings/0001193125-25-279096.md) | [0.1 d](/filings/0001193125-26-073699.md) | [1.2](/filings/0001193125-26-220696.md) | [1.4 d](/filings/0001193125-26-347988.md) | [2.2 d](/filings/0001193125-25-279096.md) | [1.2 d](/filings/0001193125-26-073699.md) | [0.2](/filings/0001193125-26-220696.md) | [0.1 d](/filings/0001193125-26-347988.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [97.0](/filings/0000950170-23-061080.md) | [98.1](/filings/0000950170-24-056869.md) | [98.4](/filings/0000950170-24-096187.md) | [98.6](/filings/0000950170-24-125317.md) | [101](/filings/0000950170-25-070285.md) | [117](/filings/0000950170-25-107309.md) | [118](/filings/0001193125-25-279096.md) | [118](/filings/0001193125-26-220696.md) | [119](/filings/0001193125-26-347988.md) | [119](/filings/0001193125-25-279096.md) | [120](/filings/0001193125-26-220696.md) | [120](/filings/0001193125-26-347988.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 119,820,514 at 2026-08-06, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-347988.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.